Julio Bobes

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)

Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case–Control Study

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case−control study

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case–control study

The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study

Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study

Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?

Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study

Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study

Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

Updated European Consensus Statement on diagnosis and treatment of adult ADHD

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study